loading...

SurePulse holds inaugural Clinical Advisory Board

  • By SurePulse
  • 25th January 2021
  • 0 Comment
  • 226 Views

We are delighted to announce that SurePulse Medical Ltd has appointed a Clinical Advisory Board and recently held the first meeting.

Chaired by Dr Don Sharkey, the Advisory Board comprises a significant breadth of backgrounds, experiences, and countries:

  • Don Sharkey is a Clinical Associate Professor of Neonatal Medicine and honorary consultant neonatologist at Nottingham University Hospitals
  • Kenda Crozier is Professor of Midwifery and International Director in the School of Health Sciences at the University of East Anglia
  • Jon Dorling is Professor of Pediatrics and Head of the Division of Neonatal-Perinatal Medicine, at Dalhousie University and the IWK Health Centre, Nova Scotia, Canada.
  • Katie Morris is Consultant Obstetrician at Birmingham Women’s Hospital and Reader in Maternal Fetal Health at the University of Birmingham
  • Yvonne Hooton is Clinical Specialist to SurePulse Medical Ltd; a Registered Sick Children’s nurse, Yvonne has been in paediatric and neonatal nursing/research for 30 years

The meeting was also attended by Barrie Hayes-Gill (Professor of Electronics and Medical Devices, University of Nottingham), Dr James Carpenter (CEO), Quentin Hayes (Commercial Manager) and Yvonne Hooton (Clinical Specialist) of SurePulse Medical Ltd.

Topics discussed included the resuscitation of newborn babies, delayed cord clamping, skin-to-skin and kangaroo care,  and vital signs monitoring.

Don Sharkey, who has a particular interest in healthcare technology for babies and children, said after the meeting: “It has been very energising to bring together such a rich mixture of backgrounds and experiences to discuss real possibilities in improving perinatal care. Newborn babies, and their mothers, deserve the best possible care and new technology, as well as evidence-based practice change, can benefit babies and their families. Importantly, these advances will also help to reduce the significant variance in outcomes between regions, communities and countries.”

Ends.

For further information please email SurePulse Medical Ltd at  info@surepulsemedical.com or telephone us on +44333 577 1133

Background:

SurePulse Medical Ltd is a joint venture between the University of Nottingham and Tioga Ltd. This collaboration combines the academic strength of the University with the commercial and manufacturing capabilities of one of the UK’s premier contract manufacturers.

Amazingly, approximately 10% of newborns (80,000/yr in UK, 14 million/yr worldwide) require some form of enhanced support or resuscitation at birth.  Reasons for this include being born too early or  with other complications such as partial umbilical cord strangulation or congenital abnormalities. Those who receive the necessary aid quickly and efficiently will generally go on to lead normal lives, however those for which this is not the case are at risk of harm including damage to their brain or blindness for example.

International guidelines recognise that the baby’s heart rate is a key indicator of how well the baby is doing and how well interventions are working, but currently there is no reliable way of measuring heart rate straight after birth. A stethoscope is the most common heart rate assessment method, but is recognised as being prone to error.

SurePulse Medical Ltd was set up to solve this dilemma. The heart rate monitor that we have developed, SurePulse VS, has now received CE approval. It uses a small and safe optical sensor mounted in a soft cap placed on the baby’s head, which also helps to keep the baby warm. The SurePulse VS monitor has been successfully trialled at the hospitals of the University of Nottingham NHS Trust.